Chapter 56: Cancer: Biochemical Foundations

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

You've tasked us with something, well, pretty monumental today.

Just a little bit.

We're synthesizing an entire chapter on cancer biology.

Specifically,

that core molecular and genetic overview of carcinogenesis.

This deep dive is our shortcut, really, to help you understand the foundational biochemistry of how a cell breaks bad.

That's right.

And we're focused entirely on the mechanisms.

So the genes, the pathways, the proteins,

all the things that let neoplasms grow, invade, and spread.

This is basically the foundation of oncology we're talking about.

It is.

And it's so important to set the stage.

Cancer is still the second most common cause of death globally.

So we're really studying the ultimate failure of a cell zone regulation.

Exactly.

And to get that clinical distinction, you really have to look at the difference between a benign tumor and a malignant one, which is true cancer.

Malignant cells, they pick up this whole toolkit of really nasty properties.

They get self -sufficiency and growth signals.

They can stimulate new blood vessels.

They lose their normal growth control.

They start ignoring death signals.

Right.

But the deadliest capability, the one that is usually responsible for patient deaths,

is the ability to move.

Metastasis.

Metastasis.

It's that invasion into local tissue and the spread to distant organs that separates an abnormal growth from a truly lethal disease.

Okay.

Let's unpack how that whole process even begins.

Carcinogenesis.

It always starts with one critical misstep, right?

Yes.

A non -lethal genetic damage event.

And that term, non -lethal, is so important.

Because if it killed the cell, well, that's the end of the story.

Precisely.

The cell has to survive that initial hit.

Then it can begin to proliferate abnormally.

And what's crucial here is that the entire mass of abnormal tissue is of clonal origin.

It all traces back to that one single cell.

That single original cell.

But we know it's not just one event.

Tumors take years, sometimes decades, to develop.

It's a multi -step process.

What influences that long progression then?

The microenvironment.

It's absolutely critical.

We call it the tissue microenvironment, or TME for short.

And that's not just cancer cells, that's everything around them.

Everything.

The immune cells, the fibroblasts, the extracellular matrix, these non -cancerous cells are constantly sending out signals that the damaged cells can hijack to fuel their own growth.

So we have an initiating genetic event.

The sources you gave us identify four broad classes of genes that are the central players here.

You've got the accelerators, the proto -oncogenes, the breaks, which are the tumor suppressor genes.

Then you have the DNA synthesis and repair genes.

The maintenance crew.

And finally, genes that help the cancer evade apoptosis cell death, or the immune system.

That initial damage, it comes from a few places.

We can classify it as either acquired or inherited.

Acquired is what most people probably think of, errors during DNA replication,

or environmental mutations from carcinogens.

Exactly.

And carcinogens can be things like radiation UV light causing pyrimidine dimers, x -rays causing strand breaks, but also chemical carcinogens.

And the chemistry here is surprisingly sophisticated.

It is.

A lot of chemical carcinogens aren't actually dangerous on their own, they're what we call pro -carcinogens.

They need an ignition switch.

A perfect way to put it.

They have to be metabolically activated, usually by cytochrome P450 enzymes in the ER, to become an electrophilic, ultimate carcinogen.

That's the active form that actually damages DNA.

So this lets us break the process into two stages.

You have the initiation, that's the irreversible genetic damage, and then promotion, which is the abnormal growth driven by ongoing exposure.

And to screen for these threats, labs use the Ames assay.

It's a really clever test using bacteria to see if a chemical is mutagenic.

But to catch those tricky pro -carcinogens, the ones that need activation.

They refine the test.

They add mammalian liver components that have those P450 enzymes.

It's a great example of biochemistry in public health.

We also can't forget oncogenic viruses.

How do they fit in?

They use a couple of main tactics.

DNA viruses like HPV will integrate their genetic material, a provirus, into the host cell.

And that doesn't directly cause cancer, does it?

Not directly.

It often works by creating proteins that actively down -regulate key tumor suppressor genes, like P53 and RB.

It neutralizes the cell's defenses.

And RNA viruses.

RNA viruses sometimes carry their own oncogenes, pre -packaged accelerators, that they just slot right into the host genome, immediately messing with cell signaling.

OK, let's dive into those accelerators then.

The oncogenes.

These are the altered versions of normal cellular genes, the proto -oncogenes.

Right.

And the key thing to remember is that they act dominantly.

One Bat -Aleel, one hit, is enough to increase their function.

So how do they get activated?

One of the most common ways is a point mutation.

A great example is the RES oncogene.

Which is a small G protein.

Exactly.

It's normally active for a moment when it's bound to GTP, but then it hydrolyzes it to shut itself off.

A point mutation can break that shut -off switch, that GTP sector.

So if the cell can't turn it off, what happens?

You get constitutively active signaling.

The MAP kinase pathway downstream is just constantly on, screaming, divide, divide, at the nucleus.

Uncontrolled proliferation.

And it's not just tiny mutations.

Big physical changes to the chromosome can do it too.

Like chromosomal translocations.

Oh, absolutely.

The classic example is Birkitt lymphoma.

A piece of chromosome 8, holding the MYC gene, gets moved and stuck right next to a really powerful immunoglobulin gene enhancer on chromosome 14.

It's like putting a tiny speaker next to a giant amplifier.

That's it, exactly.

You get this massive, unregulated overproduction of the MYC transcription factor.

And the cell is just pushed into relentless division.

The same thing happens with gene amplification, where the cell just makes dozens of copies of an oncogene.

So that's the gas pedal.

Now let's switch to the breaks.

The tumor suppressor genes, or TSGs.

These are the proteins that normally inhibit growth, and they are fundamentally different from oncogenes.

Because to lose their function, you have to get a mutation in both alleles.

It's recessive.

Correct.

This is what Nedson's famous two -hit hypothesis for retinoblastoma predicted.

You need to lose both copies of the break.

And we can split these TSGs into two functional groups.

We can.

You have the gatekeepers, which are like the cell stop signs.

They directly control the cell cycle and apoptosis.

Then you have the caretakers.

The repair crew.

The repair crew.

Their job is to preserve genomic integrity, fixing DNA damage, and keeping chromosomes stable.

And what's so clear when you look at an actual cancer is that it's never just one hit.

The progression of colorectal cancer is the perfect example of this multi -step process.

It's almost like a required sequence of events.

Exactly.

First, a mutation in the APC gene, a key gatekeeper.

Then you activate the KRAS oncogene.

Later you inactivate the P53 tumor suppressor.

It takes multiple hits across multiple classes of genes.

Right.

Now moving beyond the genome for a second, let's look at how cancer hijacks cell communication, specifically growth factors.

These are the polypeptide signals that act like keys in a lock.

They bind to receptors, kick off a whole cascade.

Often using their internal tyrosine kinase activity.

And if we take, say, the PDGF example, the binding stimulates a cascade that makes second messengers which activate kinases like protein kinase C.

And the critical outcome of all that?

The critical outcome is that this cascade rapidly triggers transcription factors in the nucleus, things like MYC and FOS, which essentially force the cell into mitosis.

Okay, and this is where it gets really interesting for me.

Non -coding RNA.

These microRNAs or mirenase.

Right.

They aren't making proteins, but they're master regulators.

They target and silence specific messenger RNAs.

And when they get dysregulated, they can directly contribute to cancer.

You basically have two types.

You have your oncomeres, which are overexpressed and act like oncogenes.

And then you have tumor -suppressive mirenase, like Let7, which are often underexpressed, so they fail to inhibit the genes they're supposed to be controlling.

Which makes them really exciting targets for new therapies.

Huge potential, both as targets and as non -invasive biomarkers.

Speaking of intercellular messengers, what about extracellular vesicles, or EVs?

Things like exosomes.

Yeah, these are fascinating.

They're these tiny sacks of material, including those non -coding RNAs that cells release.

They're like little messages sent to neighboring cells.

Influencing everything from proliferation to drug resistance.

That's exactly.

And because they're stable and they circulate in body fluids, they're another prime candidate for non -invasive biomarker testing.

We also can't ignore epigenetics here, the non -mutational changes.

The DNA sequence itself doesn't change, but how the cell reads it does.

The two big mechanisms are DNA methylation, which usually silences genes,

and histone modifications like acetylation, which affect how accessible the DNA is.

And the huge clinical takeaway here is that these changes are potentially reversible.

That's the key.

We have drugs 5 -azadioxycytidine inhibits DNA methylation, verinostat inhibits histone deacetylases, and they are already being used to treat certain leukemias by reversing the silencing of critical genes.

Okay, let's move to the engine of all this.

The cell cycle.

Cancer cells are running their engines hot.

They are.

Shorter generation times, fewer cells just sitting around in that quiescent GRO phase.

The chief guard at the gate of that cycle is the RB protein.

It is.

It normally acts as a physical lock, repressing a transcription factor called E2F to stop the cell from moving from the G1 to the S phase, the synthesis phase.

And if you lose RB function.

The break is gone.

The cell is just forced into rapid uncontrolled division.

But the central emergency break for the whole system, the true guardian of the genome, is P53.

It is.

When DNA damage happens, P53 levels go up, and it triggers one of two things.

Either cell cycle arrest to give the cell time to repair, or if the damage is too severe.

It triggers apoptosis, programmed cell death.

Yes.

But what happens when that system fails?

Disaster.

Complete disaster.

If P53 is mutated, and it is in about half of all human tumor cells with serious DNA damage, just ignore the alarm bells.

They persist and they become cancer progenitors.

Which leads directly to genomic instability, the mutator phenotype.

Exactly.

The cells become defective in their own DNA repair.

You see things like microsatellite instability, where short DNA repeats expand or contract.

And the more dramatic chromosomal instability, or CIN.

That's where you get gains or losses of entire chromosomes leading to aneuploidy.

And aneuploidy having an abnormal number of chromosomes is incredibly common in solid tumors and usually correlates with a poor prognosis.

It just gives the tumor so much more genetic diversity to work with.

And for true immortality, cancer cells have to solve one more problem.

The ends of their chromosomes.

The telomeres.

Right.

Which naturally shorten with every cell division.

Most cancer cells solve this by switching on high levels of an enzyme called telomerase.

Which normal adult cells don't really have.

They have very low levels.

Telomerase maintains telomere length, giving the cancer cell limitless replicative potential.

It's a great chemotherapy target, but a tricky one because you don't want to harm your healthy stem cells.

Shifting gears to survival, cancer cells have to evade death.

We should probably distinguish between apoptosis and necrosis here.

Good point.

Apoptosis is the clean, genetically directed process.

It involves caspases, it's non -inflammatory.

Necrosis is the messy, pathological death that causes local information.

And cancer cells have ways to evade apoptosis.

They do.

It uses two main pathways.

An extrinsic one from outside signals and an intrinsic one that's mitochondrial.

Cancer evades them both, either by losing pro -apoptotic proteins like BAX or by overexpressing anti -apoptotic survival proteins.

The most famous one is BCL2.

Now let's go back to the TME, the microenvironment, because the tumor is so much more than just cancer cells.

It's a whole ecosystem.

Immune cells, fibroblasts, endothelial cells.

And the tumor doesn't just evade the immune system.

It reprograms it.

It turns it to the dark side.

It really does.

Tumor signals manipulate immune cells like macrophages to stop attacking and instead start promoting growth, supplying growth factors, and helping with angiogenesis.

And this brings us to one of the most famous metabolic quirks in all of biology,

the Warburg effect.

Ah, yes.

Why would a rapidly dividing cell, which needs tons of energy, choose the really inefficient path of aerobic glycolysis?

Why make lactate when you have plenty of oxygen to just run oxidative phosphorylation?

That is the million dollar question.

And the why seems to be that the cancer cell prioritizes building materials over pure energy efficiency.

Okay, what does that mean?

Well, they often express a very specific low activity version of an enzyme called pyruvate kinase, the dimeric PKM2 isozyme.

This choice diverts key glycolytic intermediates away from the Krebs cycle and funnels them toward making biomass.

The lipids, the nucleic acids, the proteins,

all the stuff you need to build new daughter cells.

Precisely.

The cell doesn't want quick ATP as much as it wants the raw components or massive replication.

And this is all compounded because the hypoxia inside the tumor induces a factor called HIF1, which just ramps up glycolysis even more.

Speaking of hypoxia, tumors can't grow beyond a few millimeters without their own blood supply.

That requires angiogenesis.

Right.

New vessel growth.

And that same hypoxic core that induces HIF1 also causes a dramatic increase in the production of VEGF, vascular endothelial growth factor.

That's the tumor's signal to the host's blood vessels, telling them to grow toward it.

It is.

And that understanding led directly to one of the first targeted therapies, monoclonal antibodies like Bevacizumab, designed specifically to block VEGF and starve the tumor.

But the most lethal aspect is still metastasis.

It's responsible for something like 85 % of cancer mortality.

It's an incredibly complex and frankly inefficient process.

It involves detachment, intravization, getting into a vessel surviving in circulation, extravization, getting out, and then colonization.

And molecularly, what's driving that?

A lot of complex changes.

The cells have to decrease their cell adhesion molecules, like echinherin, to break free.

They release enzymes called matrix metalloproteinases, which are like molecular scissors that chew through the tissue.

And often this involves a process called epithelial to mesenchymal transition, or EMT, which gives them the ability to move.

So as we look at treatment, we have tumor biomarkers like PSA or CEA.

But there's a big caveat.

A huge caveat.

While they're useful for monitoring treatment, most are not specific to cancer.

PSA, for example, can be elevated in completely benign conditions.

The real game changer has been genomic analysis.

Absolutely.

Next -generation sequencing lets us distinguish between the driver mutations, the ones actually causing the cancer, and the harmless passenger mutations.

This is what powers precision oncology.

And it leads directly to these life -changing targeted therapies.

The poster child is imotinib or Gleevec.

A total revolution for chronic myelocytic leukemia.

By targeting that specific unregulated tyrosine kinase from the ABL -BCR translocation, it completely transformed patient outcomes.

And now the newest pillar is immunotherapy.

Using things like anti -PD -1 antibodies.

Right.

They work by removing the breaks that tumors place on our own T -cells, unleashing the immune system to attack the cancer.

Drug resistance is always the challenge, of course, but our deep dive into these mechanisms is the only way we make progress.

That was an absolutely essential synthesis of the core principles.

Thank you for sharing these sources and letting us unpack such critical material.

The key takeaways for you, the learner, are pretty clear.

First, cancer is driven by genetic mutations in oncogenes and tumor suppressor genes that mess up key signaling and cell cycle checkpoints.

Second, the tumor's behavior really depends on manipulating its microenvironment and adopting these radical metabolic programs, like the Warburg effect.

And third,

understanding these exact molecular mechanisms is what's powering all of modern personalized medicine.

Exactly.

And here's a final provocative thought for you to consider.

Given that the cancer stem cell pool often resists chemotherapy because it's dormant and has great DNA repair, how might future therapies evolve to specifically target these critical resistant progenitors without also harming the body's healthy stem cells, which share many of the same traits?

That is the challenge.

Keep exploring these complex interactions.

It's a field that promises to reshape human health.